Marstacimab-hncq

Brand names: Hympavzi · Active ingredient: Marstacimab

In short: HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: •hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or •hemophilia B (congenital factor IX defic

Forms & strengthsHYMPAVZI (marstacimab‑hncq) is a clear and colorless to light yellow solution available as: Prefilled Syringe •Injection: 150 mg/mL in a single-dose prefilled syringe •Injection: 75 mg/0.5 mL in a single-dose prefilled syringe Prefilled Pen •Injection: 150 …
LabelPfizer Laboratories Div Pfizer Inc
Label updatedNov 16, 2026

What is Marstacimab-hncq used for?

HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:

•hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or

•hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.

⚠ Boxed warning (FDA's strongest warning)

•

Venous and arterial thromboembolic events were reported in patients treated with HYMPAVZI with thrombotic risk factors .

•

Monitor patients for signs or symptoms of thromboembolism and interrupt use of HYMPAVZI if these occur and manage as clinically indicated .

Marstacimab-hncq dosage

For subcutaneous use only.

The recommended dosage of HYMPAVZI for adults and pediatric patients 12 years of age and older is as follows:

Loading Dose

300 mg (two 150 mg subcutaneous injections)

If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

Maintenance Dose

One week after the loading dose, initiate maintenance dosing of 150 mg every week by subcutaneous injection on the same day each week, at any time of day.

Dose Adjustment During Treatment

In patients weighing greater than or equal to 50 kg, consider a dose adjustment to 300 mg subcutaneous injection weekly when control of bleeding events is judged to be inadequate by the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 300 mg weekly have not been established.

If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

Missed Doses

For patients on a maintenance dose of 150 mg:If a dose is missed, administer as soon as possible before the day of the next scheduled dose, and then resume usual 150 mg subcutaneous weekly dosing schedule (same schedule as prior to the missed dose or new schedule based on date of administration of missed dose).

If more than 13 days have passed since the last dose was administered, administer a loading dose of 300 mg by subcutaneous injection followed by a resumption of 150 mg by subcutaneous injection once weekly thereafter.

For patients on a maintenance dose of 300 mg:If one or more doses are missed, administer a dose as soon as possible, and then resume 300 mg subcutaneous weekly dosing schedule (same schedule as prior to the missed dose or new schedule based on date of administration of missed dose).

For subcutaneous use only.

The recommended dosage of HYMPAVZI for pediatric patients 6 to less than 12 years of age is as follows:

Loading Dose

150 mg (one 150 mg subcutaneous injection or two 75 mg subcutaneous injections)

If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

Maintenance Dose

One week after the loading dose, initiate maintenance dosing of 75 mg every week by subcutaneous injection on the same day each week, at any time of day.

Dose Adjustment During Treatment

In patients weighing greater than or equal to 25 kg, consider a dose adjustment to 150 mg subcutaneous injection (one 150 mg subcutaneous injection or two 75 mg subcutaneous injections) weekly when control of bleeding events is judged to be inadequate by the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 150 mg weekly have not been established in children 6 to less than 12 years of age. …

How to take Marstacimab-hncq — instructions & advice from the label

•Advise the patient and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

•Ensure that patients and caregivers who will administer HYMPAVZI receive appropriate training and instruction on the proper storage, use and handling of HYMPAVZI from a healthcare professional.

Thromboembolic Events

Inform patients and/or caregivers that HYMPAVZI increases coagulation potential. Discuss the appropriate dosing of concomitant agents such as FVIII or FIX with the patient prior to starting on HYMPAVZI prophylaxis. Inform patients of signs and symptoms of thromboembolic events, including swelling, warmth, pain or redness in the arms or legs; shortness of breath; pain in chest or upper back; rapid heart rate; coughing up blood; faintness or dizziness; sudden or severe headache; numbness of the face; eye pain or swelling; vision problems; confusion; difficulty with speech; weakness or numbness on one side of the body. Advise the patient to discontinue HYMPAVZI and seek immediate medical attention if any signs or symptoms of thromboembolism occur . …

Warnings & precautions

Do not take this medicine if: None.

HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist, and may increase the risk of thromboembolic complications. Venous and arterial thromboembolic events were reported in 0.8% of patients (2/259) treated with HYMPAVZI in the open-label extension study

, including one patient with inhibitors who died due to complications resulting from an event of cerebral infarction post-surgery. These cases occurred in patients with multiple risk factors for thromboembolic events. Thromboembolic events were also reported in the postmarketing setting.

Risk factors for thromboembolism may include the use of high and/or frequent doses of breakthrough bleed treatments (factor products or bypassing agents) or conditions in which tissue factor is overexpressed (e.g., atherosclerotic disease, crush injury, cancer, disseminated intravascular coagulation, thrombotic microangiopathy, or septicemia).

Monitor patients for signs or symptoms of thromboembolism and interrupt use of HYMPAVZI if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated.

HYMPAVZI has not been studied in patients with a history of previous thromboembolic events . Consider the benefit and risk of using HYMPAVZI in patients with known risk factors for thromboembolism.

If factor VIII or factor IX products or bypassing agents are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose according to the product label is recommended . Inform patients of signs and symptoms of thromboembolic events. Monitor patients for thromboembolic events. If a thromboembolic event is suspected, discontinue HYMPAVZI and initiate appropriate medical treatment.

HYMPAVZI may cause hypersensitivity reactions (including but not limited to urticaria and pruritus). …

Marstacimab-hncq side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

•Thromboembolic Events

•Hypersensitivity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of HYMPAVZI was evaluated in adults and pediatric patients 6 years of age and older with severe hemophilia A (FVIII <1%) or moderately severe to severe hemophilia B (FIX ≤2%) with and without inhibitors enrolled in the BASIS and BASIS KIDS studies. A total of 259 patients received the recommended HYMPAVZI prophylaxis loading dose followed by a weekly maintenance dose starting at Day 8 administered subcutaneously . One-hundred-thirty-five (52%) were adults (18 years of age and older), 56 (22%) were adolescents (12 to less than 18 years of age), and 68 (26%) were children (6 to less than 12 years of age). Among patients receiving HYMPAVZI, 90% were exposed for 6 months or longer and 82% were exposed for at least 1 year. The median duration of exposure across the studies was 364 days (min, max: 14, 406 days).

Table 1 summarizes the adverse reactions reported in ≥2% of patients in all age groups who received HYMPAVZI prophylaxis. …

Drug interactions

Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT)

No clinically significant differences in standard measures of coagulation including activated partial thromboplastin time (aPTT) and prothrombin time (PT) were observed following marstacimab‑hncq therapy.

About this medicine

Marstacimab‑hncq is a tissue factor pathway inhibitor (TFPI) antagonist, human monoclonal immunoglobulin G Type 1 (IgG1) antibody. Marstacimab‑hncq is produced by Chinese hamster ovary (CHO) cells by recombinant DNA technology and has a molecular mass of approximately 146 kDa.

HYMPAVZI (marstacimab‑hncq) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose prefilled syringe or as a single‑dose prefilled pen. The solution of marstacimab‑hncq is clear and colorless to light yellow with a pH of 5.8.

Each 150 mg/mL prefilled syringe or prefilled pen delivers 1 mL of HYMPAVZI. Each 1 mL of HYMPAVZI contains 150 mg of marstacimab‑hncq, and the inactive ingredients edetate disodium (0.05 mg), histidine (1.12 mg), L-histidine monohydrochloride (2.67 mg), polysorbate 80 (0.2 mg), and sucrose (85 mg), in Water for Injection, USP.

Each 75 mg/0.5 mL prefilled syringe or prefilled pen delivers 0.5 mL of HYMPAVZI. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a2cc631e-13a6-40c2-acf9-065ccedfb90a. Read the full official label on DailyMed.